Recent Updates
Recently added Catalysts
HTFL Positive Sentiment

Elucid Statement on Heartflow Lawsuit: Reaffirms Mission, Confidence in Its Technology, and Commitment to Patients and Physicians

Key Takeaway: Elucid Bioimaging Inc. reaffirmed its mission to prevent heart attacks and strokes amid a lawsuit from Heartflow, Inc. filed on October 22, 2026. The company expressed confidence in its technology and plans to defend against the claims. Elucid remains committed to supporting patients and physicians.

Market Sentiment Analysis

POSITIVE FACTORS

  • Elucid reaffirms commitment to its mission.
  • Confidence in technology and intellectual property.
  • Focus on preventing heart attacks and strokes.

Full Press Release Details

BOSTON--(BUSINESS WIRE)--Elucid Bioimaging Inc. (“Elucid”) today reaffirmed its commitment to advancing its mission – the prediction and personalization of the prevention of heart attack and stroke – and its confidence in the technology and intellectual property behind its products. Elucid is aware of a lawsuit filed by Heartflow, Inc., on October 22, 2026. Elucid will respond to and defend against the claims in the lawsuit through the appropriate legal channels. “Elucid was founded to help phy

Frequently Asked Questions

What is the lawsuit against Elucid about?

The lawsuit was filed by Heartflow, Inc. on October 22, 2026.

How is Elucid responding to the lawsuit?

Elucid plans to respond and defend against the claims through legal channels.

What is Elucid's mission?

Elucid's mission focuses on predicting and personalizing the prevention of heart attacks and strokes.

What technology does Elucid rely on?

Elucid has confidence in its technology and intellectual property behind its products.

Last updated: Oct 23, 2026